PFE logo
Pfizer Inc.
PFE
26.92 (-1.10%) 0.30
Health Care
Pharmaceuticals
Pfizer Inc. discovers develops manufactures markets distributes and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma PC1 and Pfizer Ignite. The company offers internal medicine products including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family Abrysvo Nimenrix FSME/IMMUN-TicoVac and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products such as Xeljanz Enbrel Cibinqo Litfulo Eucrisa and Velsipity; rare disease products for therapeutic areas comprising amyloidosis hemophilia and endocrine diseases under the Vyndaqel family Genotropin BeneFIX Xyntha Somavert Ngenla and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta Octagam and Panzyga brands. In addition the company offers oncology products comprising ADCs small molecules bispecific and other immunotherapies for the treatment of cancers including breast cancer genitourinary cancer and hematologic malignancies as well as melanoma gastrointestinal gynecological and lung cancer under the Ibrance Xtandi Padcev Adcetris Inlyta Lorbrena Bosulif Tukysa Braftovi Mektovi Orgovyx Elrexfio Tivdak and Talzenna brands. Further it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit Ruxience Zirabev Trazimera and Nivestym and other biosimilars; and sterile injectables such as Sulperazon Atgam Fragmin Solu Medrol Solu Cortef and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US Inc.; Merck KGaA; and BioNTech SE as well as a strategic collaboration with Boltz PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York New York.

Quality Checklist 3/8

Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
5Y Shares Out Change < 0%
ROIC > 10%
Quick Ratio > 1
Past Net Income CAGR > 0%
Est. EPS Growth > 5%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $153.13(B)
EV: $214.59(B)
Total Equity: $86.78(B)
Earnings date: May-05-2026
P/E: 19.65
Forward P/E: 9.09
P/FCF: 16.82
P/S: 2.45
P/B: 1.77
EPS: $1.4
EPS (fwd): $3.0
FCF/share: $1.6
Revenue/share: $11.0
Book value/share: $15.2
ROIC: 6.3%
ROA: 4.6%
ROE: 10.6%
Debt/Equity: 0.78
Current Ratio: 1.20
Gross margin: 75.8%
Operating margin: 24.6%
Net margin: 12.4%
Dividend/share: $1.7
Div. yield: 6.39%

PFE Valuation & Price Targets

Current Price
$26.9

Favorite Valuation Methods

More Valuation Methods

DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
DDM
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A

PEvaluation

58% undervalued
Low
$31.9
Mid
$42.6
High
$53.2
Current price
$26.9
Fair P/E
Margin of safety
EPS
Market Model
ROICRevenue growthFCF MarginShares outstan...Debt/EquityDebt/EBITDA
Economic moat: Wide

EPS Estimates

LowAvgHigh#
FY+12.83.03.226
FY+22.52.83.025
FY+32.02.42.918
FY+41.72.12.512
FY+51.52.22.712

Analyst Price Targets

0% undervalued
Low
$25.0
Mid
$27.0
High
$36.0
Current price
$26.9

Analyst Recommendations

Strong Buy2
Buy8
Hold15
Sell1
Strong Sell2

2-stage DCF

First Stage Duration: 5 Years
Starting Free Cash Flow
First Stage Growth Rate
LowMidHigh
Terminal Growth Rate
LowMidHigh
Discount Rate

Discounted Cash Flow

Forecast years: 5 Years
Terminal Growth Rate
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years
Exit FCF Multiple
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years
First Stage Growth Rate
Final Growth Rate
Discount Rate

EPS Growth

Forecast years: 5 Years
Starting EPS
EPS Growth Rate
LowMidHigh
Final P/E
LowMidHigh
Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years
Base Revenue
Revenue Growth Rate
LowMidHigh
Final Net Margin
LowMidHigh
Final P/E Ratio
LowMidHigh
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate